What type of study is this?

September 10, 2025

A Rare Case of Thrombotic Thrombocytopenic Purpura Developed During Nivolumab Treatment in a Patient with Hodgkin Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Case report details TTP occurrence in Hodgkin lymphoma treatment with nivolumab, highlighting potential complications.

The case presents a rare instance of TTP development after nivolumab treatment.
Nivolumab is an anti-PD-1 monoclonal antibody formulated for Hodgkin lymphoma.
The findings underline the importance of monitoring hematological toxicities from immune therapies.
Clinical awareness is crucial for identifying potential complications linked to immune checkpoint inhibitors.

derya deniz kürekci (2025) studied this question.

View Full Paper

Ask AI

Bookmark